Negative impact of sedation on esophagogastric junction evaluation during esophagogastroduodenoscopy

Table 2 Endoscopy-related outcomes among the groups n (%)

	No sedation	Midazolam	Propofol	P value
	(n = 35)	(n = 35)	(n = 33)
Indications				0.084
Screening	28 (80.0)	25 (71.4)	17 (51.5)
Epigastric discomfort/pain	5 (14.3)	6 (17.2)	14 (42.6)
Peptic ulcer disease follow-up	1 (2.9)	1 (2.9)	2 (6.0)
Others	1 (2.9)	3 (8.6)	0 (0.0)
Endoscopic findings
Reflux esophagitis	4 (11.4)	2 (5.7)	2 (6.1)	0.726
Hiatal hernia	0 (0.0)	3 (8.6)	0 (0.0)	0.105
Peptic ulcer disease	3 (8.6)	2 (5.7)	2 (6.1)	1.000
Gastric polyp	2 (5.7)	2 (5.7)	1 (3.0)	1.000
Neoplasm	0 (0.0)	2 (5.7)	0 (0.0)	0.327
Adverse event
Hiccoughing	0 (0.0)	9 (25.7)	3 (90.0)	0.002
Hypoxia	0 (0.0)	0 (0.0)	2 (6.1)	0.101